NCT00194714: Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

NCT00194714
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HLA+
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: Female
Age: 19 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must be HLA-A2 positive
Exclusions: 
https://ClinicalTrials.gov/show/NCT00194714

Comments are closed.

Up ↑